Direct Acting Antiviral-Post Authorization Safety Study

Screening Inclusion Criteria: * Current participant in TARGET-HCC * Adults, age ≥18 years * First diagnosis of HCC (mixed HCC/cholangiocarcinoma may be included). Diagnosis may be histological/cytological and/or radiological. * BCLC Stage A * Underwent, undergoing, or planned to undergo therapy for HCC, with exception that transplant as prior or planned treatment for HCC is excluded. * HCV RNA positive Screening Exclusion Criteria: * Inability to provide informed consent * HCC-free imaging (as defined in Section 9.1.1) after treatment of initial HCC prior to Screening (see Section 9.2.9 for imaging details) * Prior liver transplantation * Hepatitis B Virus (HBV) surface antigen positive (HBsAg) * Previously treated with direct-acting antiviral agents (not DAA-naïve); Note that prior (peg)IFN and/or ribavirin therapy is allowed Enrollment Inclusion Criteria: * Continued participation in TARGET-HCC * No recurrence or progression of initial HCC beyond BCLC Stage A prior to Enrollment/Baseline * HCC-free imaging (as defined in Section 9.1.1) at Enrollment/Baseline (see Section 9.2.9 for imaging details; participants may remain in Screening until an HCC-free image is obtained) * Remains DAA-naïve (prior therapy with (peg)IFN and/or ribavirin is allowed) Enrollment Exclusion Criteria: \- Liver transplantation since Screening